Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients–A prospective controlled study DOI Creative Commons
Cecilie R. Buskbjerg, Ali Amidi, Mads Agerbæk

et al.

Cancer Medicine, Journal Year: 2021, Volume and Issue: 10(18), P. 6249 - 6260

Published: Aug. 13, 2021

Previous research has indicated cognitive decline (CD) among testicular cancer patients (TCPs), even in the absence of chemotherapy, but little is known about underlying pathophysiology. The present study assessed changes functions and structural brain connectomes TCPs explored associations between endocrine status hypothesized risk genotypes.Thirty-eight newly orchiectomized 21 healthy controls (HCs) comparable to terms age years education underwent neuropsychological testing, MRI, a biological assessment at baseline 6 months later. Cognitive change was with test battery determined using standardized regression-based approach, substantial defined as z-scores ≤-1.64 or ≥1.64. MRI scans graph theory were used evaluate connectomes. testosterone levels, androgen receptor gene (AR) CAG repeat length, genotypes (APOE, COMT, BDNF) explored.Compared HCs, showed higher rates on processing speed visuospatial ability improvement verbal recall learning (p < 0.05; OR = 8.15-15.84). Brain network analysis bilateral thalamic node degree not 0.01). In TCPs, levels predicted memory 0.05). No effects found for AR APOE, BDNF.The confirms previous findings domain-specific CD following orchiectomy, also points improvements. results do indicate be main drivers CD. Further studies evaluating mechanisms including possible role dynamics hypothalamic-pituitary-gonadal axis, are warranted.

Language: Английский

APOE in the normal brain DOI Creative Commons
Sarah A. Flowers, G. William Rebeck

Neurobiology of Disease, Journal Year: 2020, Volume and Issue: 136, P. 104724 - 104724

Published: Jan. 6, 2020

The APOE4 protein affects the primary neuropathological markers of Alzheimer's disease (AD): amyloid plaques, neurofibrillary tangles, and gliosis. These interactions have been investigated to understand strong effect APOE genotype on risk AD. However, has effects processes in normal brains, absence hallmarks We propose that CNS is involved brains later years apply specifically AD pathogenesis. review differences found compared plasma, including post-translational modifications (glycosylation, lipidation, multimer formation), focusing ways common isoforms differ from each other. also structural functional studies young human control knock-in mouse brains. approaches demonstrate microscopic neuron structure, gross brain behavior, primarily related hippocampal areas. By function, can be pursued identify biomarkers dysfunction, promote functions isoform, prevent accumulation pathologic with aging.

Language: Английский

Citations

113
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? DOI
Sanne B. Schagen, Andrey S. Tsvetkov, Annette Compter

et al.

Nature Reviews Neurology, Journal Year: 2022, Volume and Issue: 18(3), P. 173 - 185

Published: Feb. 9, 2022

Language: Английский

Citations

65
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116) DOI
Stephen R. Rapp, Emily V. Dressler, W. Mark Brown

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(21), P. 2546 - 2557

Published: May 6, 2024

To test efficacy of donepezil, a cognitive enhancer, to improve memory in breast cancer survivors who report cancer-related impairment 1-5 years postchemotherapy.

Language: Английский

Citations

7
A narrative review of risk factors and interventions for cancer- related cognitive impairment DOI Open Access
Lu Bai, Enyan Yu

Annals of Translational Medicine, Journal Year: 2021, Volume and Issue: 9(1), P. 72 - 72

Published: Jan. 1, 2021

Abstract: Cancer-related cognitive impairment (CRCI) refers to a series of symptoms associated with alternations in brain structure and function, caused by non-central nervous system malignant tumor its related treatment. CRCI may present as memory loss, impaired concentration, difficulty multitasking word retrieval, reduced comprehension speed. has become one the prevalent factors that compromise quality life for cancer survivors. Different treatments, including surgery, chemotherapy, radiotherapy, endocrine therapy, targeted drugs, contribute CRCI. Meanwhile, patients' factors, emotional challenges genetic makeup, also development The condition can be treated using stimulants methylphenidate modafinil, metabolites nicotine: cotinine, antidepressants fluoxetine fluvoxamine, dementia drug donepezil, antioxidants ZnSO4, n-acetyl cysteine, propofol, Chinese herbal silver leaf medicine. Psychotherapies, meditation relaxation, rehabilitation training, along physical therapies, aerobic exercise, resistance balance yoga, qigong, tai chi electroencephalogram biofeedback, acupuncture, are beneficial alleviating cancer-related symptoms. In recent years, researchers have focused on available interventions. However, most research was conducted independently, no review yet summarized latest findings. This details discusses status potential treatments We supply specific recommendations facilitate future integration this field.

Language: Английский

Citations

38
Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment DOI Creative Commons

Zhimeng Yao,

Hongmei Dong,

Jianlin Zhu

et al.

JCI Insight, Journal Year: 2023, Volume and Issue: 8(14)

Published: July 23, 2023

Chemotherapy-related cognitive impairment (CRCI) or "chemo brain" is a devastating neurotoxic sequela of cancer-related treatments, especially for the elderly individuals. Here we show that PTPRO, tyrosine phosphatase, highly enriched in hippocampus, and its level tightly associated with neurocognitive function but declined significantly during aging. To understand protective role PTPRO CRCI, mouse model was generated by treating Ptpro-/- female mice doxorubicin (DOX) because are more vulnerable to DOX, showing impairments neurodegeneration. By analyzing substrates neurocognition-associated kinases, found SRC EPHA4 phosphorylated/activated hippocampi mice, increased sensitivity DOX-induced CRCI. On other hand, restoration hippocampal CA3 region ameliorate CRCI mice. In addition, plant alkaloid berberine (BBR) capable ameliorating aged upregulating PTPRO. Mechanistically, BBR upregulates downregulating miR-25-3p, which directly targeted These findings collectively demonstrate against

Language: Английский

Citations

11
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study DOI Creative Commons

Mylène Duivon,

François Christy,

Emilie Thomas

et al.

Breast Cancer Research, Journal Year: 2025, Volume and Issue: 27(1)

Published: Feb. 19, 2025

Language: Английский

Citations

0
Chemotherapy-related cognitive impairment and kidney dysfunction DOI Creative Commons
Mariadelina Simeoni, Michele M. Mulholland, Biruh Workeneh

et al.

Nephrology Dialysis Transplantation, Journal Year: 2025, Volume and Issue: 40(Supplement_2), P. ii54 - ii63

Published: March 1, 2025

ABSTRACT Cancer and kidney diseases (KD) intersect in many ways resulting worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated cancer patients by known effects of antineoplastic drugs on cognition, leading to a phenomenon as chemotherapy-related impairment (CRCI). This manifests poor attention span, disturbed short-term memory, general mental sluggishness. literature review explores CRCI investigates the potential impact KD this phenomenon. Additionally, we highlight shared pathogenetic mechanisms (including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, electrolyte, acid-base imbalances), clinical presentation imaging findings between CRCI. The disruption blood–brain barrier might key mechanism for increased brain permeability anticancer nephropathic cancer. Based existing knowledge, found heightened neurotoxicity synergistic potentiation KD. However, further translational research is urgently required validate hypothesis.

Language: Английский

Citations

0
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: A scoping review DOI Creative Commons
Kate Oppegaard, Terri S. Armstrong, Joaquin A. Anguera

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2022, Volume and Issue: 180, P. 103822 - 103822

Published: Sept. 21, 2022

Language: Английский

Citations

17
The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment DOI Creative Commons
Michelle C. Janelsins, Kathleen Van Dyk, Sheri J. Hartman

et al.

JNCI Journal of the National Cancer Institute, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Abstract Cancer-related cognitive impairment is a broad term encompassing subtle problems to more severe impairment. The severity of this influenced by host, disease, and treatment factors, the affects patients before, during, following cancer treatment. National Cancer Institute (NCI) Symptom Management Health-Related Quality Life Steering Committee (SxQoL SC) convened clinical trial planning meeting review state science on cancer-related develop phase II/III intervention trials aimed at improving function in survivors with non–central nervous system disease longitudinal studies understand trajectory contributing factors. Participants included experts field impairment, members SxQoL SC, patient advocates, representatives from all 7 NCI Community Oncology Research Program research bases, NCI. Presentations focused topics: measurement, lessons learned pediatric geriatric oncology, biomarker mechanism endpoints, study designs, pharmacological behavioral trials. Panel discussions provided guidance priority assessments, considerations for remote inclusion relevant biomarkers, strategies ensuring criteria. Three working groups (longitudinal as well trials) 1 year discuss report top priorities design studies. concluded that sufficient data exist advance using selected interventions setting, recommendations herein.

Language: Английский

Citations

3
Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms DOI Open Access
Rebecca A. Harrison, Noha Sharafeldin, Jennie L. Rexer

et al.

The Oncologist, Journal Year: 2021, Volume and Issue: 26(11), P. e2021 - e2033

Published: June 22, 2021

Hematopoietic stem cell transplant (HSCT) plays a central role in the treatment of hematologic cancers. With increasing survival patients after HSCT, survivorship issues experienced by this population have become an important outcome. Cognitive impairment is established sequela with studies to date establishing its presence, associated risk factors, and clinical phenotype. There are multiple potential contributors cognitive HSCT. Efforts ongoing further characterize phenotype, biomarkers, biologic underpinnings. A fundamental knowledge post-HSCT value for all clinicians who interface population, academic efforts needed more fully understand impact cancer on brain health. IMPLICATIONS FOR PRACTICE: As outcomes hematopoietic improve, awareness post-treatment challenges faced has care. HSCT can sustained broad health, causing dysfunction, fatigue, disturbed mood, sleep. In affected patients, autonomy, return work, relationships, quality life may be affected. fluency area interfacing survivors, facilitating identification management dysfunction concurrent symptom clusters, stimulating interest these sequelae as areas future research.

Language: Английский

Citations

20